No Data
Cantor Fitzgerald Maintains Ascendis Pharma A/S(ASND.US) With Buy Rating, Raises Target Price to $200
Express News | Cantor Fitzgerald Maintains Overweight on Ascendis Pharma, Raises Price Target to $200
Ascendis Pharma to Participate in the TD Cowen 45th Annual Health Care Conference
Morgan Stanley Maintains Ascendis Pharma A/S(ASND.US) With Hold Rating, Maintains Target Price $180
FIRST AND ONLY TREATMENT FOR CHRONIC HYPOPARATHYROIDISM APPROVED IN AUSTRALIA
Why Is BioMarin Stock Trading Higher On Thursday?
factors that put the rise on are not from a rebound but from news, either way the price is above the price before financial reporting
